Antifungal prophylaxis with anidulafungin to minimize drug interactions with an antiepileptic treatment in a hematopoietic stem cell transplant recipient.
WHAT IS KNOWN AND OBJECTIVE
Invasive fungal infections are a major cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). This provides a clear rationale for antifungal prophylaxis in this population. A concern is the potential for drug interactions, given that most of antifungals are metabolized through the P450 cytochrome system.


CASE SUMMARY
We present a case of a 33-year-old woman, with a past history of high-risk epilepsy, who underwent allogeneic HSCT for a myelodysplastic syndrome. Anidulafungin was successfully used as antifungal prophylaxis to minimize drug interactions with her antiepileptic treatment.


WHAT IS NEW AND CONCLUSION
This is the first reported case of antifungal prophylaxis with this echinocandin in HSCT. Anidulafungin may be an option in transplant recipients with multiple risk factors for drug interactions.
['Feliu|J|J|', 'Del Pozo|J L|JL|', 'Azanza|J R|JR|', 'García-Muñoz|R|R|', 'Zabalza|A|A|', 'Gorosquieta|A|A|', 'Pérez-Equiza|E|E|', 'Olavarría|E|E|']
antifungal prophylaxis anidulafungin drug interactions hematopoietic stem cell transplantation